India Glycols demerger gets NCLT nod for 2026 split

What the NCLT order means for India Glycols

India Glycols Ltd (IGL) has moved a step closer to completing a long-running restructuring after the National Company Law Tribunal (NCLT), Allahabad Bench, sanctioned its demerger scheme. The company disclosed that it has received the tribunal’s order dated July 17, 2026, which approves a Scheme of Arrangement involving India Glycols, Ennature Bio Pharma Ltd, and IGL Spirits Ltd. The company said the order was uploaded on the NCLT website on July 20, 2026. Separately, the company also indicated it formally received the certified true copy of the NCLT order on August 20, 2026. The approved plan splits IGL’s operations into three distinct entities by carving out two undertakings into separate companies. For shareholders, the key detail is that the resulting businesses are intended to be in separate listed entities, with a fixed share entitlement ratio.

Three-entity structure: who gets what

Under the sanctioned scheme, India Glycols remains the demerged company and will transfer two undertakings into two resulting companies. The biopharma business is to be transferred to Ennature Bio Pharma Limited. The spirits and biofuel business is to be transferred to IGL Spirits Limited. This separation is designed to ring-fence business lines that have different operating cycles and investor profiles. The scheme documents, as described by the company, relate to the demerger of the Biopharma and the Spirits and Biofuel undertakings. The case and filings describe the arrangement as a Scheme of Arrangement among the three companies. The tribunal proceeding relates to the corporate restructuring framework under the Companies Act.

Key dates investors should track

The NCLT order was pronounced on July 17, 2026, according to the case update. India Glycols has also stated the “appointed date” for the demerger is April 1, 2026. The company has not disclosed an “effective date” yet and said it will announce that separately after completing remaining legal and regulatory formalities. In other words, while the scheme is sanctioned, the operational and listing-related steps still need to be completed before the demerger becomes effective. Investors typically watch for filings related to regulatory clearances, record date communication, and listing or trading approvals for resulting entities. The company’s disclosures indicate the effective date will be communicated once procedural requirements are met.

Share entitlement ratio under the scheme

A central part of any demerger is the share entitlement mechanism, and India Glycols has laid out the swap ratio in its exchange disclosure. Shareholders of India Glycols will receive shares in both resulting companies, based on their holdings in IGL. For every three equity shares held in India Glycols, shareholders will receive one equity share of Ennature Bio Pharma. Additionally, shareholders will receive one equity share of IGL Spirits for every one equity share held in India Glycols. These ratios define how ownership in the carved-out undertakings will be distributed to existing shareholders. The company has positioned this as a distribution of interests in the two separated businesses to IGL’s shareholder base.

What the tribunal sanctioned and the legal framework

The NCLT Allahabad Bench at Prayagraj sanctioned the scheme of arrangement involving India Glycols Limited, Ennature Bio Pharma Limited, and IGL Spirits Limited. The restructuring was executed in accordance with Sections 230 to 232 of the Companies Act, 2013, as described in the case update. The tribunal’s order is linked to the case titled “INDIA GLYCOLS LIMITED, ENNATURE BIO PHARMA LIMITED & IGL SPIRITS LIMITED” with citation “2026 LLBiz NCLT (ALL) 755”. The case number referenced in the update is CP (CAA) NO.07/ALD/2026. These details matter for investors and analysts who track legal milestones and verify scheme status through official records and tribunal uploads.

How the process progressed: hearings and reserved order

The demerger moved through multiple procedural steps before the final sanction. An earlier stage included an NCLT order dated April 9, 2026, which directed newspaper publications and regulatory notices with a 30-day response period, and set the next hearing for May 21, 2026. Later, the NCLT Allahabad Bench reserved its order on July 2, 2026, after hearing the second motion petition, as referenced in the updates. The reserved order was subsequently pronounced on July 17, 2026. This sequence reflects the typical route for schemes of arrangement, where the tribunal reviews notices, stakeholder responses, and compliance submissions before granting sanction.

Market reaction: stock edges lower after the update

Following the developments, India Glycols shares were reported to have slipped 0.13% to settle at ₹1,155.00 in post-market trading. The move indicates a relatively muted immediate reaction, despite the milestone nature of the tribunal sanction. In corporate actions like demergers, market pricing often depends on clarity around the effective date, record date, and listing timelines for resulting entities. Investors also watch for operational separation details and how the company will present segment performance going forward. Since the company has indicated further formalities remain, some market participants may be waiting for the next set of disclosures.

Snapshot table: scheme details at a glance

What happens next: effective date and remaining formalities

India Glycols has said it will announce the effective date separately after completing remaining legal and regulatory formalities. This suggests the company is still working through steps required to operationalise the scheme, including implementation filings and approvals linked to corporate and securities regulations. For shareholders, the next practical milestones typically include communication around the effective date and the record date that determines eligibility for share allotment in the resulting companies. The company’s future stock exchange updates will be important for clarity on timelines and procedural completion. Until then, the key confirmed facts remain the NCLT sanction, the appointed date, and the share entitlement ratios.

Why the restructuring matters for investors and tracking

A demerger can change how investors analyse a company by separating businesses with different growth drivers and risk profiles. In this case, the scheme clearly demarcates biopharma into Ennature Bio Pharma and the spirits and biofuel undertaking into IGL Spirits. After implementation, investors may evaluate each business on its own operational performance and sector-specific metrics, rather than as part of a consolidated structure. The tribunal sanction also reduces uncertainty around whether the scheme will proceed, though timing certainty depends on the effective date and follow-through on formalities. With the legal milestone in place, the next phase is execution and disclosures around how the three-entity structure will function post-demerger.

Conclusion

India Glycols has received the NCLT Allahabad Bench’s sanctioned order for its demerger scheme, with the order pronounced on July 17, 2026, and the certified true copy received on August 20, 2026. The scheme transfers the biopharma undertaking to Ennature Bio Pharma and the spirits and biofuel undertaking to IGL Spirits, with specified share entitlements for IGL shareholders. The appointed date is April 1, 2026, while the effective date is yet to be announced. The next confirmed step is the company’s disclosure of the effective date after it completes remaining legal and regulatory formalities.